Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Engaging in the Recommended Amount of Physical Activity May Help Prevent 7 Cancer Types

January 7, 2020
By Hannah Slater
Article

Though physical activity guidelines are largely based on chronic diseases like cardiovascular disease and diabetes, these data suggest they are important to cancer prevention as well.

According to a study published in the Journal of Clinical Oncology, engagement in the recommended amount of leisure-time physical activity (7.5-15 MET hours/week) was associated with lower risk for 7 different cancer types.1

While it has previously been known that physical activity is associated with a lower risk for several cancers, it was unclear if guideline recommended amounts of physical activity were associated with lower risk.2

“Physical activity guidelines have largely been based on their impact on chronic diseases like cardiovascular disease and diabetes,” Alpa Patel, PhD, senior scientific director of epidemiology research at the American Cancer Society, said in a press release. “These data provide strong support that these recommended levels are important to cancer prevention, as well.” 

In this cohort of 755,459 participants, individuals were followed for 10.1 years, and 50,620 incident cancers accrued during that time. Engagement in recommended amounts of activity were associated with a statistically significant lower risk for 7 of the 15 cancers studied, including colon (8%-14% lower risk in men), breast (6%-10% lower risk), endometrial (10%-18% lower risk), kidney (11%-17% lower risk), myeloma (14%-19% lower risk), liver (18%-27% lower risk), and non-Hodgkin lymphoma (11%-18% lower risk in women).

Both moderate- and vigorous-intensity activity seemed to be associated with lower risk for colon, breast, and kidney cancer, but the sample size for other cancer types was too limited to draw conclusive data. Adjustment for BMI eliminated the association with endometrial cancer but had a limited effect on other cancer types. 

Approximately half of the cancers associated with physical activity were found to have linear dose-response curves (colon, breast, endometrial, and head and neck cancer, as well as esophageal adenocarcinoma), with the lowest risk at levels well above the recommended minimum level of activity. For several cancers with a curvilinear association (kidney, gastric, and liver cancer), most of the risk reduction observed was associated with recommended amounts of physical activity. 

“This finding may explain in part previous observations that higher levels of activity were needed to achieve significantly lower risk of colon and breast cancer,” the authors wrote. “Given these linear associations, substantially lower relative risk estimates may have only been observable at higher activity levels in previous studies, particularly given smaller participant numbers and more limited statistical power in individual studies.” 

Additionally, the difference in the strength of associations for engaging in 7.5-15 MET hours/week when comparing results for breast cancer and liver cancer may reflect relevant differences in the underlying biologic mechanisms for distinct cancer types. These findings might indicate that there are fundamentally different physical activity dose-response relationships for all-cause and cardiovascular mortality and some cancers and sizable variation in the underlying biologic mechanisms that link physical activity to different types of cancer, however additional research is needed. 

Furthermore, researchers suggested that these findings provide actionable evidence for ongoing and future cancer prevention efforts, including the guidance that health care providers, fitness professionals, and public health practitioners should encourage adults to adopt and maintain physical activity at recommended levels.

References:

1. Matthews CE, Moore SC, Arem H, et al. Amount and Intensity of Leisure-Time Physical Activity and Lower Cancer Risk. Journal of Clinical Oncology. doi:10.1200/JCO.19.02407.

2. Report links recommended physical activity levels to lower risk of seven cancers [news release]. Published December 26, 2019. eurekalert.org/pub_releases/2019-12/acs-rlr122319.php. Accessed January 3, 2020.

Recent Videos
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Related Content
Advertisement

Evaluating the Rapidly Changing ADC Landscape in HR+/HER2– Breast Cancer

Evaluating the Rapidly Changing ADC Landscape in HR+/HER2– Breast Cancer

Kit Yu Lu, MD;Naeem Latif, MD;Monica Khunger Malhotra, MD;Sudhamshi Toom, MD;Shannon L. Puhalla, MD;Theresa Marguerite Lee, MD;Andrew William Swartz, MD;Sri Lakshmi Hyndavi Yeruva, MD
May 21st 2025
Article

"The data, even in fast progressors and within 6 months of endocrine therapy, [show it] is working," stated Monica Khunger Malhotra, MD.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


ODAC Votes 6-2 For Benefit-Risk Profile of SQ Daratumumab in High-Risk Smoldering Multiple Myeloma

ODAC Votes 6-2 For Benefit-Risk Profile of SQ Daratumumab in High-Risk Smoldering Multiple Myeloma

Tim Cortese
May 20th 2025
Article

Based on the trial population and end point criteria, ODAC voted for daratumumab and hyaluronidase-fijh injection for SQ use in high-risk smoldering multiple myeloma.


Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Manojkumar Bupathi, MD, MS;Manojkumar Bupathi, MD, MS
May 1st 2025
Podcast

Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.


3 Things You Should Know About Advances in CLL Management

3 Things You Should Know About Advances in CLL Management

ONCOLOGY Staff
May 20th 2025
Article

Care for patients with chronic lymphocytic leukemia continues to evolve via novel targeted therapies. Here are 3 things every cancer care specialist should know about treating CLL.


In the UK, the Medicines and Healthcare products Regulatory Agency approved the belantamab mafodotin combinations in April 2025 based on findings from the DREAMM-7 and DREAMM-8 trials.

Belantamab Mafodotin Earns Japanese Approval in R/R Multiple Myeloma

Russ Conroy
May 19th 2025
Article

Data from the DREAMM-7 and DREAMM-8 trials support the approval of belantamab mafodotin for patients with relapsed/refractory multiple myeloma in Japan.

Related Content
Advertisement

Evaluating the Rapidly Changing ADC Landscape in HR+/HER2– Breast Cancer

Evaluating the Rapidly Changing ADC Landscape in HR+/HER2– Breast Cancer

Kit Yu Lu, MD;Naeem Latif, MD;Monica Khunger Malhotra, MD;Sudhamshi Toom, MD;Shannon L. Puhalla, MD;Theresa Marguerite Lee, MD;Andrew William Swartz, MD;Sri Lakshmi Hyndavi Yeruva, MD
May 21st 2025
Article

"The data, even in fast progressors and within 6 months of endocrine therapy, [show it] is working," stated Monica Khunger Malhotra, MD.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


ODAC Votes 6-2 For Benefit-Risk Profile of SQ Daratumumab in High-Risk Smoldering Multiple Myeloma

ODAC Votes 6-2 For Benefit-Risk Profile of SQ Daratumumab in High-Risk Smoldering Multiple Myeloma

Tim Cortese
May 20th 2025
Article

Based on the trial population and end point criteria, ODAC voted for daratumumab and hyaluronidase-fijh injection for SQ use in high-risk smoldering multiple myeloma.


Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Manojkumar Bupathi, MD, MS;Manojkumar Bupathi, MD, MS
May 1st 2025
Podcast

Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.


3 Things You Should Know About Advances in CLL Management

3 Things You Should Know About Advances in CLL Management

ONCOLOGY Staff
May 20th 2025
Article

Care for patients with chronic lymphocytic leukemia continues to evolve via novel targeted therapies. Here are 3 things every cancer care specialist should know about treating CLL.


In the UK, the Medicines and Healthcare products Regulatory Agency approved the belantamab mafodotin combinations in April 2025 based on findings from the DREAMM-7 and DREAMM-8 trials.

Belantamab Mafodotin Earns Japanese Approval in R/R Multiple Myeloma

Russ Conroy
May 19th 2025
Article

Data from the DREAMM-7 and DREAMM-8 trials support the approval of belantamab mafodotin for patients with relapsed/refractory multiple myeloma in Japan.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.